Unjoni Ewropea - Malti - EMA (European Medicines Agency)

eli lilly nederland b.v. - insulina lispro - diabetes mellitus - drogi użati fid-dijabete - trattament tad-dijabete mellitus f'adulti, adolexxenti u tfal ta 'sena u aktar. trattament tad-dijabete mellitus fl-adulti.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

eli lilly nederland b.v. - insulina lispro - diabetes mellitus - drogi użati fid-dijabete - għat-trattament ta 'adulti u tfal b'dijabete mellitus li jeħtieġu l-insulina għall-manteniment ta' omeostasi normali tal-glukożju. humalog huwa indikat ukoll għall-istabbilizzazzjoni inizjali tad-dijabete mellitus.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

eli lilly nederland b.v. - tadalafil - disfunzjoni erettili - uroloġiċi - trattament ta 'disfunzjoni erettili. sabiex tadalafil ikun effettiv, l-istimulazzjoni sesswali hija meħtieġa. cialis mhuwiex indikat għall-użu min-nisa.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

eli lilly and company limited  - fentanyl - sistema nervuża - klieb - għall-kontroll ta 'uġigħ assoċjat ma' kirurġija ortopedika u tessut artab fil-klieb.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

teva pharma b.v. - ibandronic acid - breast neoplasms; neoplasm metastasis; fractures, bone; osteoporosis, postmenopausal - drogi għat-trattament ta 'mard tal-għadam - ibandronic acid 50mgibandronic-aċidu teva huwa indikat għall-prevenzjoni ta ' episodji skeletriċi (fratturi patoloġiċi, komplikazzjonijiet fl-għadam li jeħtieġu r-radjuterapija jew il-kirurġija) f'pazjenti b'kanċer tas-sider u metastażi fl-għadam. ibandronic acid 150mgtreatment of osteoporosis in postmenopausal women at increased risk of fracture. tnaqqis fir-riskju ta ' ksur vertebrali ġie muri, l-effikaċja fuq il-ksur fl-għonq tal-femora ma ġietx stabbilita.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

merck sharp dohme ltd - boceprevir - epatite Ċ, kronika - antivirali għal użu sistemiku - victrelis huwa indikat għall-kura ta ' l-infezzjoni tal-ġenotip-1 kronika epatite-c (chc), flimkien mal-peginterferon alfa u ribavirin, fil-pazjenti adulti b ' mard tal-fwied kompensat li huma mhux ittrattat minn qabel jew li jkunu fallew terapija qabel.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

smithkline beecham plc - rosiglitazone, metformin hydrochloride - diabetes mellitus, tip 2 - drogi użati fid-dijabete - avandamet huwa indikat fit-trattament tad-dijabete tat-tip 2 mellitus il-pazjenti, l-aktar dawk b'piż żejjed:li ma laħqux kontroll gliċemiku suffiċjenti fl-għola doża ttollerata ta ' metformin mill-ħalq waħdu. f'terapija orali trippla ma 'mediċina tat-tip sulphonylurea, f'pazjenti b'kontroll gliċemiku insuffiċjenti minkejja terapija doppja mill-ħalq bl-ogħla doża ttollerata ta' metformin u sulphonylurea (ara sezzjoni 4.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

roche registration ltd. - ibandronic acid - l-osteoporożi, il-menopawża - drogi għat-trattament ta 'mard tal-għadam - trattament ta 'l-osteoporożi f'nisa wara l-menopawża b'riskju akbar ta' ksur. tnaqqis fir-riskju ta ' ksur vertebrali ġie muri. l-effikaċja fuq tal-femora-għonq ksur għadha ma ġietx stabbilita.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - empagliflozin - diabetes mellitus, type 2; heart failure; renal insufficiency, chronic - drogi użati fid-dijabete - type 2 diabetes mellitusjardiance is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered in addition to other medicinal products for the treatment of diabetesfor study results with respect to combinations of therapies, effects on glycaemic control, and cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 u 5. of the annex. heart failurejardiance is indicated in adults for the treatment of symptomatic chronic heart failure.  chronic kidney diseasejardiance is indicated in adults for the treatment of chronic kidney disease.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - aġenti antitrombotiċi - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.